Basit öğe kaydını göster

dc.contributor.authorTahan, Veysel
dc.contributor.authorOzaras, Reşat
dc.date.accessioned2021-03-03T16:40:50Z
dc.date.available2021-03-03T16:40:50Z
dc.date.issued2009
dc.identifier.citationOzaras R., Tahan V., "Acute hepatitis C: prevention and treatment", EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, cilt.7, sa.3, ss.351-361, 2009
dc.identifier.issn1478-7210
dc.identifier.othervv_1032021
dc.identifier.otherav_45906b26-8738-4dce-bc73-2980b4c74724
dc.identifier.urihttp://hdl.handle.net/20.500.12627/50419
dc.identifier.urihttps://doi.org/10.1586/eri.09.8
dc.description.abstractHCV can cause acute or chronic hepatitis and is a health problem all over the world. It is one of the leading causes of cirrhosis and hepatocellular carcinoma, and is a common indication for liver transplantation. Unrecognized patients with HCV infection may transmit the virus to uninfected people. The acute form of the disease leads to chronic hepatitis in the majority of cases. Since the success rate of treatment given in the chronic phase is much lower than that given in the acute phase, recognizing acute hepatitis is critical. Although HCV is less prevalent since 1990s in the Western world after improved blood-donor screening programs, needle-exchange facilities and education among intravenous drug users, it is still endemic in some regions, including African countries, Egypt, Taiwan, China and Japan. Acute HCV infection may be a challenge for the clinician; since it is often asymptomatic, detection and diagnosis are usually difficult. After an incubation period of 7 weeks (2-12 weeks), only a minority of patients (10-15%) report symptoms. The spontaneous clearance of the virus is more frequent primarily during the first 3 months of clinical onset of the disease, but may occur anytime during the 6 months of acute infection. This spontaneous resolution seems to be more frequent in symptomatic cases. Viremia persisting more than 6 months is accepted as chronic infection. The virus is transmitted more frequently through infected blood or body fluids. Detection of antibodies against HCV is not a reliable method of diagnosing acute HCV infection since the appearance of antibodies against HCV can be delayed in up to 30% of patients at the onset of symptoms. Thus, the diagnosis of acute hepatitis C relies on the qualitative detection of HCV RNA, which may appear as early as 1-2 weeks after exposure quickly followed by highly elevated alanine aminotransferase. After a follow-up period of 8-12 weeks for allowing spontaneous resolution, treatment should be initiated. Pegylated interferon monotherapy for 24 weeks seems effective, and the therapy can be individualized according to the characteristics of the patient.
dc.language.isoeng
dc.subjectTemel Eczacılık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectEczacılık
dc.subjectSağlık Bilimleri
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectMikrobiyoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectİmmünoloji
dc.subjectBULAŞICI HASTALIKLAR
dc.titleAcute hepatitis C: prevention and treatment
dc.typeMakale
dc.relation.journalEXPERT REVIEW OF ANTI-INFECTIVE THERAPY
dc.contributor.departmentMarmara Üniversitesi , ,
dc.identifier.volume7
dc.identifier.issue3
dc.identifier.startpage351
dc.identifier.endpage361
dc.contributor.firstauthorID64646


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster